Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome

The main objective will be to check if MyoInositol (MYO) reduces the total resistance rate to Clomiphene Citrate (CC). For this, our study will be controlled, randomized and double blinded. It will include patients with PCOS (polycystic ovary syndrome, defined by the Rotterdam criteria) who wish to become pregnant and are eligible to simple ovulation induction by CC. Half of them will receive MYO + levomefolic acid (5-MTHF) in addition to the CC, while the other half will receive a placebo containing only 5-MTHF in addition to the CC. The MYO supplementation will be initiated at least one month before taking CC and will be continued throughout this treatment until pregnancy or before switching to another type of treatment for ovulation induction if no pregnancy is obtained after 6 ovulatory cycles.

NCT Number	NCT03059173
Lead Sponsor	University Hospital, Lille Collaborators: Ministry of Health, France, Laboratoires Besins International
Conditions	Polycystic Ovary Syndrome, Reproductive Medicine
Enrollment	276 participants
Start Date	2023-09-12
Primary Completion	2027-09-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-04-22